Lisinopril use in chronic kidney disease
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril and Renal Function in Chronic Kidney Disease
Lisinopril, an angiotensin-converting enzyme inhibitor (ACEi), is widely used in the management of chronic kidney disease (CKD), particularly for its renoprotective effects. Studies have shown that lisinopril can slow the progression of renal insufficiency in patients with non-diabetic CKD and mild proteinuria, offering benefits beyond blood pressure control. In a clinical trial, patients treated with lisinopril experienced significantly less decline in renal function compared to those on other antihypertensive agents, even when blood pressure was similarly controlled in both groups. The risk of reaching critical endpoints such as the need for dialysis or halving of glomerular filtration rate (GFR) was also lower with lisinopril use, supporting its specific renoprotective effect in CKD patients with mild proteinuria .
Lisinopril and Proteinuria Reduction in CKD
Lisinopril has demonstrated a strong ability to reduce proteinuria in both adult and pediatric CKD populations. In adults with nondiabetic chronic nephropathies, increasing lisinopril doses led to a significant and dose-dependent reduction in proteinuria, which was associated with improvements in lipid profiles and serum albumin levels. These effects were more pronounced in patients with hypoalbuminemia, and the benefits persisted even after treatment withdrawal . In children with CKD, lisinopril therapy resulted in a notable reduction in proteinuria within the first six months, although the effect diminished after about three years, indicating the need for ongoing dose adjustments or alternative therapies over time .
Lisinopril’s Impact on Lipid Abnormalities and Cardiovascular Risk
CKD is often accompanied by dyslipidemia, which increases cardiovascular risk. Lisinopril not only reduces proteinuria but also improves lipid abnormalities, particularly by lowering total and LDL cholesterol and triglycerides. These improvements are linked to the drug’s effect on nephrotic syndrome and are especially significant in patients with low serum albumin. The reduction in triglycerides is directly related to lisinopril dosage and reverses after stopping the medication, while cholesterol improvements are tied to better protein status .
Lisinopril in Pediatric CKD and Hypertension
Long-term studies in children with CKD and hypertension have shown that lisinopril is effective in achieving blood pressure targets and reducing proteinuria. However, its efficacy for blood pressure control may decline after 2.5 years, and proteinuria reduction may wane after three years, highlighting the importance of regular monitoring and potential therapy adjustments. Additionally, aldosterone breakthrough—a phenomenon where aldosterone levels rise despite ACEi therapy—was observed after six months, suggesting a need for careful long-term management .
Lisinopril’s Role in Slowing CKD Progression and Reducing Renal Damage
Experimental studies in animal models of CKD, including diabetic and non-diabetic nephropathies, have shown that lisinopril can slow the decline in GFR, reduce glomerular damage, and decrease interstitial fibrosis and tubular atrophy. When combined with other agents such as SGLT2 inhibitors or GLP-1 receptor agonists, lisinopril further improves renal outcomes, including better control of hypertension, reduced albuminuria, and less severe glomerulosclerosis 79. In models of polycystic kidney disease, chronic lisinopril treatment reduced both proliferative and apoptotic pathways, leading to less cyst development and complete amelioration of proteinuria .
Lisinopril’s Anti-Inflammatory and Antioxidant Effects
Lisinopril’s renoprotective benefits are partly due to its anti-inflammatory and antioxidant properties. In animal studies, lisinopril reduced markers of inflammation and oxidative stress, improved biochemical and histopathological indices, and was as effective as other renin-angiotensin system modulators in reversing CKD-related damage .
Safety and Tolerability of Lisinopril in CKD
Across multiple studies, lisinopril was generally well tolerated in both adult and pediatric CKD populations. Adverse events were infrequent and typically reversible, with symptomatic hypotension being rare. In pediatric cohorts, careful dose titration and monitoring were emphasized to maintain efficacy and minimize side effects 24.
Lisinopril in Kidney Transplant Recipients
In kidney transplant patients with hypertension, lisinopril was effective and safe for blood pressure control. However, compared to calcium channel blockers like nifedipine, lisinopril did not improve graft function over a two-year period, suggesting that its renoprotective benefits may be more pronounced in native CKD rather than in the transplant setting .
Conclusion
Lisinopril is a cornerstone therapy in the management of chronic kidney disease, offering significant benefits in slowing disease progression, reducing proteinuria, improving lipid profiles, and providing anti-inflammatory and antioxidant effects. Its efficacy is well established in both adult and pediatric populations, though long-term management may require dose adjustments or combination therapy. Lisinopril’s safety profile is favorable, making it a valuable option for nephroprotection in CKD.
Sources and full results
Most relevant research papers on this topic